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Abstract
Standard treatment of poisoning by organophosphorus anticholinesterases uses atropine
to reduce the muscarinic effects of acetylcholine accumulation and oximes to reactivate
acetylcholinesterase (the effectiveness of which depends on the specific anticholinester-
ase), but does not directly address the nicotinic effects of poisoning. Bispyridinium mole-
cules which act as noncompetitive antagonists at nicotinic acetylcholine receptors have
been identified as promising compounds and one has been shown to improve survival fol-
lowing organophosphorus poisoning in guinea-pigs. Here, we have investigated the struc-
tural requirements for antagonism and compared inhibitory potency of these compounds at
muscle and neuronal nicotinic receptors and acetylcholinesterase. A series of compounds
was synthesised, in which the length of the polymethylene linker between the two pyridi-
nium moieties was increased sequentially from one to ten carbon atoms. Their effects on
nicotinic receptor-mediated calcium responses were tested in muscle-derived (CN21) and
neuronal (SH-SY5Y) cells. Their ability to inhibit acetylcholinesterase activity was tested
using human erythrocyte ghosts. In both cell lines, the nicotinic response was inhibited in a
dose-dependent manner and the inhibitory potency of the compounds increased with
greater linker length between the two pyridinium moieties, as did their inhibitory potency for
human acetylcholinesterase activity in vitro. These results demonstrate that bispyridinium
compounds inhibit both neuronal and muscle nicotinic receptors and that their potency
depends on the length of the hydrocarbon chain linking the two pyridinium moieties. Knowl-
edge of structure-activity relationships will aid the optimisation of molecular structures for
therapeutic use against the nicotinic effects of organophosphorus poisoning.
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Introduction
The acute toxicity of organophosphorus (OP) pesticides and nerve agents is a result of inhibi-
tion of acetylcholinesterase (AChE), leading to accumulation of acetylcholine (ACh) at both
muscarinic and nicotinic acetylcholine receptors; however, current pharmacotherapy focuses
only on the muscarinic component, using the competitive muscarinic antagonist, atropine.
The consequences of nicotinic overstimulation include paralysis of respiratory and other skele-
tal muscles, which is a major factor in the lethal effects of AChE inhibitors.
The paralysis produced by anticholinesterases is initially believed to result from depolarisa-
tion block of the muscle membrane due to potentiation and prolongation of the endplate
potential as a result of the prolonged residence time of ACh in the synaptic cleft. During a
period of repetitive (tetanic) stimulation, the force generated by the muscle rapidly fades as the
muscle membrane becomes depolarised without a refractory period. This is known as depolari-
sation block because the muscle is unable to respond to new stimuli as it is already in a depo-
larised state [1–3]. Over a longer timescale, continuous stimulation by ACh causes the receptor
to become insensitive to ACh binding [4, 5]. Failure of neuromuscular transmission during
AChE inhibition is thus a combination of depolarisation block and receptor desensitisation.
The interaction between these two processes is apparent after a prolonged period of AChE
inhibition, when the ability of a neuromuscular preparation to sustain a tetanic contraction
returns slightly. The mechanism of this adaptation is believed to be chronic desensitisation of
the postsynaptic nicotinic receptors, which results in a reduction of the endplate potential
amplitude and duration [1, 6]. The muscle membrane is then able to repolarise and undergo a
refractory period, restoring contractile function. It has even been suggested that agents that
accelerate desensitisation at the neuromuscular junction could be useful in the treatment of
anticholinesterase poisoning [6].
Although the nicotinic effects can be treated indirectly, by the use of an oxime to reactivate
inhibited acetylcholinesterase, each acetylcholinesterase-inhibitor complex differs in its suscep-
tibility to reactivation by different oximes. Moreover, some complexes under a process called
aging which renders them impossible to reactivate. This means that no one oxime will be effec-
tive against all of the OPs, making a generic therapy based on this mechanism unlikely [7].
In contrast, an appropriate antinicotinic drug (reviewed in [8]) should be able to treat the
nicotinic effects of poisoning regardless of the OP involved, in the same way that the effective-
ness of muscarinic antagonists is independent of the OP. The reason why nicotinic antagonists
are not currently used [9] is largely due to the difficulties of administering a dose of competitive
nicotinic neuromuscular blocker sufficient to antagonise the effects of excessive acetylcholine,
but not so great that it paralyses the muscles [10].
An alternative approach would be to use a noncompetitive antagonist whose effects would
not be overcome by increasing concentrations of acetylcholine. Certain bispyridinium com-
pounds [11], including some oximes, have a beneficial effect in organophosphorus poisoning,
which correlates with their ability to block the open ion channel of the nicotinic receptor [12].
Open channel block, a form of noncompetitive antagonism, appears to be an ideal way of miti-
gating the effects of excessive activation of nAChRs because the block is use-dependent: antag-
onism becomes greater as channel activation increases. This is the converse of what happens
with a competitive antagonist.
We recently synthesised a novel bispyridinium compound which blocks the open ion chan-
nel of the muscle-type nicotinic receptor and we demonstrated that this noncompetitive antag-
onism, as well as reversing the neuromuscular blocking action of nerve agent in vitro, can
protect animals against poisoning by nerve agents when used as part of a therapeutic drug
combination [13, 14]. We have now synthesised a series of compounds based on this structure.
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We followed the approach to structure–activity relationship used previously by [15], who char-
acterized the chain length dependence of potency of bis-quartenary N+ separated by poly-
methylenes of different chain lengths.
In this study, we demonstrate that the bis-pyridinium compounds interact not only with
muscle-type nAChRs, but also with neuronal nAChRs containing only α and β subunits, and
that the strength of the interactions with muscle nicotinic receptor, neuronal nicotinic receptor
and acetylcholinesterase all depend on the length of the polymethylene chain linking the two
pyridinium moieties. Understanding of structure-activity relationships will be valuable for
optimising molecular structures for therapeutic use.
Material and Methods
Drugs and chemicals
Bispyridinium compounds (Fig 1), in which the polymethylene chain linking the two pyridi-
nium rings was increased in length from C1 to C10, were synthesised as the diiodide salts at
Dstl Porton Down and were>98% pure. These salts are easily accessible through quaternisa-
tion of two molar equivalents of pyridine with α,ω-diiodoalkanes [16] and many could be
made in a short space of time for in vitro screening. The nature of the counterion is expected to
have a negligible effect on the ion channel blocking activity as the latter depends on the nature
of the cation. Unless otherwise noted, all proprietary drugs and chemicals were purchased
from Sigma-Aldrich Ltd. (Poole, Dorset, UK).
Cell culture
CN21 cells, derived from the TE671 human rhabdomyosarcoma cell line [17] by a stable trans-
fection of the ε-subunit to express both the foetal (α1, γ, α1, ß1, δ) and adult human (α1, ε, α1,
ß1, δ) muscle nicotinic receptor, were a gift from Dr David Beeson (Institute of Molecular
Medicine, John Radcliffe Hospital, Oxford, UK) [18]. The cells were grown using standard cell
culture techniques in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich, UK) with 10%
Foetal Bovine Serum (Invitrogen, UK), 50 units ml-1 penicillin, 50 μg ml-1 streptomycin, 2 mM
L-glutamine (Sigma-Aldrich, UK) and 0.5 mg ml-1 geneticin (Invitrogen, UK) and grown in
150 cm2 cell culture flasks until approximately 70–80% confluent in a humidified atmosphere
in an incubator at 36.5°C with 5% CO2. Cells were then harvested using 0.25% trypsin/ethyle-
nediamine tetraacetic acid (EDTA) solution (Sigma-Aldrich, UK) in Ca2+/Mg2+-free phosphate
buffered saline and were collected by centrifugation (100 g, 4 min). For maintenance, cells were
re-plated into culture flasks at split ratios of 1:6–1:10. Cells were used in experiments between
passages 2 and 8 following recovery from cryopreservation.
The human neuroblastoma cell line SH-SY5Y expresses several nicotinic receptor subunits
(α3, α5, α7, β2 and β4), giving rise to multiple neuronal nicotinic receptor subtypes [19], which
makes it a good model for investigating neuronal responses to nicotinic receptor activation.
SH-SY5Y cells, generation 14, were obtained from the European Collection of Cell Cultures
(ECACC, Salisbury, UK), scaled up and stored in ampoules at -135°C in the regular growth
medium supplemented with 10% DMSO. Cells (generation 19–25) were grown in Minimum
Essential Medium with Earle’s salts, GlutaMax-I, 10% Foetal Bovine Serum (all Invitrogen,
Norway) and 0.1 mg ml-1 Gentamycin sulfate in poly-L-lysine coated 75 ml cell culture flasks
at 36°C in a humidified atmosphere with 5% CO2. The medium was changed after one day to
remove remnants of DMSO and again after 3–4 days. The cells were subdivided into new flasks
with a split ratio of 1:10 every 6–8 days. The medium was removed and cells were harvested
with the aid of 0.02% EDTA in phosphate buffered saline (i.e. without trypsin). Cells were
detached with a tap on the flask and growth medium was added to the suspended cells which
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were collected by centrifugation (100 g, 3 min). For experiments, cells were plated at 1:10 dilu-
tion into poly-L-lysine coated 96-well black Cellbind flat transparent bottom plates (Corning,
USA) and experiments were performed 72 h later with semiconfluent cultures.
Nicotinic calcium response assay
CN21 cells were plated out onto clear-bottomed, black-walled, tissue culture treated 96-well
plates (Corning Costar) at a density of ~20,000 cells per well in 100 μl of medium (so that they
approached confluence after 24 h) for subsequent experimentation. The growth medium was
removed, leaving the cells adhering to the bottom of the plate and 50 μl of a Calcium 4 assay kit
dye (Fluo-4 acetoxymethylester, Molecular Devices FLIPR Calcium 4 assay kit, Molecular
Devices, Union City, California, USA) in a HEPES-buffered balanced salt solution (NaCl 135
mM, KCl 5.4 mM, CaCl2 1 mM, MgCl2 1 mM, HEPES acid 5 mM, NaHCO3 3.6 mM, D-glu-
cose 10 mM, pH 7.4 with NaOH) was added and the cells were incubated in the dark for ~30
min. Cells were not washed prior to assay as the FLIPR Calcium 4 assay kit also contained a
quenching dye to minimise fluorescence from extracellular de-esterified (fluorescent) Fluo-4.
The dye loading solution also contained atropine (20 μM) to block the muscarinic response
and pharmacologically isolate the nicotinic response to acetylcholine.
The test compounds were dissolved as stock solutions in HEPES-buffered solution on the
day of the experiment. After the cells had been incubated with the dye, dilutions of this stock
solution (12 μl) were added to each well on the cell plate to achieve the final desired concentra-
tions. The first and last columns received a vehicle control so that the compound response
could be compared to the vehicle at the beginning and end of each experiment to allow evalua-
tion of time-dependent effects. Each compound was tested at 10 different concentrations in
duplicate on each plate and each experiment was conducted 3 times.
For testing, plates were transferred to a FlexStation II fluorescence plate reader (Molecular
Devices Limited, UK) and the fluorescence intensity was measured at ~1 s intervals prior to
and after addition of 58 μl of 20 μM acetylcholine to achieve a final concentration in each well
of ~10 μM, which gave approximately 80% of the maximal response (EC80). Excitation and
emission wavelengths were set to 485 nm and 525 nm respectively, with a cut-off of 515 nm.
All measurements were made at room temperature (~21°C). Agonist additions were made
automatically using the plate reader’s in-built dispensing functions. Baseline fluorescence was
measured for 20 s, followed by addition of acetylcholine. Further measurements of fluorescence
for 80 s were then made to follow the agonist-induced response.
Responses were quantified as the maximum response expressed as a percentage of the aver-
age baseline values. For analysis, these data were then normalised to the mean vehicle control
values for the wells in the corresponding row. Responses were fitted to a standard four-parame-
ter logistic equation using GraphPad Prism version 4.00 for Windows (GraphPad Software,
San Diego, California, USA) and a log IC50 and Hill slope with standard errors (SEM) were
determined. For analysis of the lower potency compounds, curve fitting assumed a maximal
Fig 1. Molecular structure of the bispyridinium compounds tested.
doi:10.1371/journal.pone.0135811.g001
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inhibition equivalent to that obtained with the higher potency C7-C10 compounds where max-
imal inhibition could be fitted. This value was constrained in the analyses of the lower potency
data allowing an estimation of the IC50.
SH-SY5Y cells grown in multiwell plates were loaded with fura-2 by incubating in growth
medium with 2 μM fura-2 AM (Invitrogen, UK), 0.02% pluronic (Invitrogen) and 1 mM pro-
benecid, the latter to inhibit fura-2 secretion [20]. Cells were incubated at 36°C for 45 min and
then in the growth medium alone for ~35 min for de-esterification. The cells were then washed
once with experimental buffer (140 mMNaCl, 3.5 mM KCl, 1 mMMgSO4, 2 mM CaCl2,1.2
mMNa2HPO4, 15 mM Tris-HCl, 5 mM glucose, 1 mMMgSO4) before adding experimental
buffer with the drug tested to a total volume of 200 μl per well. Probenecid at 1 mM was added
to all experimental buffers.
For testing, plates were transferred to a fluorescence plate reader equipped with injectors
(Fluostar Optima, BMG Labtech, Germany). Nicotine was diluted to 250 μM in experimental
buffer and filled in the injector. The plate was then placed in the plate reader set at a tempera-
ture of 32°C. The injection speed was 100 μl s-1, and the total injection volume was 50 μl, the
final concentration then being 50 μM nicotine.
Fluorescence excitations were at 340 nm and 380 nm (10 nm bandwidths) and low pass
emission at 505 nm, both in bottom reading mode (i.e. from underneath the plate). Time reso-
lution was limited by the speed of filter wheel change to 1.5 s per sampling point. The total
measurement time for each well was 30 s. The agonist was injected under the computerised
control of the plate reader after 8 s (to determine first a baseline for each well individually) and
the area under the curve for the last 15 s of emission was determined. The average background
fluorescence from 340 nm and 380 nm excitation was determined from a plate with cultures of
SH-SY5Y cells not loaded with fura-2 and the response in each well was taken as the change in
the "340/380 ratio", i.e. the change in the ratio of emission from excitations at 340 nm and 380
nm in each well. Response calculations were automated off-line with an in-house programme
for fura-2 and 96-well plates written in Origin (OriginLab, USA). IC50 values were determined
in a similar way to the analysis of responses for CN21 cells by fitting the four-parameter logistic
equation to the ratiometric responses using GraphPad Prism version 4.00.
Acetylcholinesterase inhibition assay
Human erythrocyte ghosts served as the acetylcholinesterase source and were prepared from
heparinized human blood. As confirmed by the Bavarian Medical Association, the investiga-
tion of blood samples was not considered a clinical study under German regulations and there-
fore did not require formal approval by an ethics committee.
Hemoglobin-free erythrocyte ghosts were prepared as described previously [21]. In brief,
heparinized human blood was centrifuged (3000 x g, 10 min) and the plasma removed. Eryth-
rocytes were washed with 2 volumes of phosphate buffer (3 times; 0.1 M, pH 7.4) and the
packed erythrocytes were diluted in 20 volumes of hypotonic phosphate buffer (6.7 mM, pH
7.4) followed by centrifugation (50.000 x g, 30 min, 4°C). The supernatant was removed, the
pellet re-suspended in hypotonic phosphate buffer and the procedure was repeated twice.
Then, the pellet was re-suspended in phosphate buffer (0.1 M, pH 7.4), the virtually hemoglo-
bin-free erythrocyte ghosts were concentrated by centrifugation at 100,000 x g (30 min, 4°C)
and, finally, the AChE activity was adjusted to the original activity (i.e. 4–5 U/ml) by appropri-
ate dilution with phosphate buffer (0.1 M, pH 7.4). Aliquots of the erythrocyte ghosts were
stored at -80°C until use. In order to achieve a homogenous matrix for the kinetic studies, ali-
quots were homogenized on ice three-times for 5 sec with 30 sec intervals with a Sonoplus HD
2070 ultrasonic homogenator (Bandelin electronic, Berlin, Germany).
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Acetylcholinesterase activities were measured spectrophotometrically with a liquid handling
system (Freedom EVO, Tecan, Männedorf, Switzerland) connected to a microplate reader
Safire2 (Tecan) with a modified Ellman assay [22, 23] using 96-well microplates and 0.45 mM
acetylthiocholine iodide (Sigma-Aldrich, Deisenhofen, Germany) as substrate and 0.3 mM
5,5’-dithiobis(2-nitrobenzoic acid) (DTNB; Sigma) as a chromogen in 0.1 M phosphate buffer
(pH 7.4, 37°C).
The inhibitory potency of the test compounds C1-C10 was assessed in duplicate by incuba-
tion of acetylcholinesterase with 10−9–10−3 M for 5 min before adding substrate to determine
enzyme activity. Acetylcholinesterase activities were referred to activity of native acetylcholin-
esterase and were expressed as percentage of control. IC50 values were determined in a similar
way to the analysis of responses for CN21 and SH-SY5Y cells by fitting a four parameter logis-
tic equation (GraphPad Prism 4.00).
Results
Nicotinic response in CN21 cells
When CN21 cells were exposed to acetylcholine in the presence of atropine (20 μM) to block
the muscarinic response, an influx of Ca2+ could be measured using the Ca2+-sensitive fluores-
cent dye Fluo-4. This response peaked in less than 10 s and could be completely blocked by the
addition of the nicotinic antagonist d-tubocurarine (50 μM) [13]. When KCl at concentrations
of 10–100 mM was used to depolarise the cells without addition of acetylcholine, no response
was elicited (data not shown), confirming that the response was due to activation of nAChRs.
The concentration-dependence of the nicotinic response is shown in Fig 2. The response
increased rapidly from a negligible change in fluorescence at 0.3 μM acetylcholine to a plateau
of the maximum response from 30 to 300 μM, declined at higher concentrations. To enable a
parametric fit of the data shown in Fig 2, concentrations above 300 μMwere removed from the
analysis and a sigmoidal concentration-response curve was fitted to the data, revealing a Hill
slope greater than 1. Using these data, an agonist concentration of 10 μMACh, which repre-
sented an approximate EC80 of the response, was selected for subsequent experiments using
the test compounds.
Effect of the test compounds on CN21 cells
Each compound was tested on CN21 cells at 10 concentrations, decreasing by half-log steps
from 3 mM. All of the compounds produced a concentration-dependent inhibition of the nico-
tinic response (Fig 3). The inhibitory potency of the series of compounds increased with longer
linker length (Table 1). The C1 to C5 compounds generally had a limited effect on the nicotinic
response at the concentrations tested here, but the C6 to C10 compounds all produced a potent
block of the response (Fig 3). The C9 and C10 compounds had almost identical profiles of
activity in this assay. All the Hill slope values (Table 1) were less negative than -1, except for
the C9 and C10 compounds which produced steeper slopes (closer to -1.5).
Nicotinic response in SH-SY5Y cells
In preliminary experiments (not shown), SH-SY5Y cells cultured on poly-L-lysine coated glass
coverslips were exposed to nicotine, 10–100 μM. The single cell measurements showed
responses with an increase in intracellular Ca2+ which peaked in 15–40 s depending on the ago-
nist concentration and the size of the response.
For the remainder of the experiments, SH-SY5Y cells were cultured in 96-well plates. Fig 4
shows the concentration-response relationship for nicotine and the effect of one of the test
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compounds (MB779, C10) on the concentration-response curve. The responses were
completely blocked by mecamylamine, a selective neuronal nicotinic receptor inhibitor, and by
d-tubocurarine, with EC50 values of 0.025 μM and 0.66 μM, respectively. A concentration of
50 μM nicotine, corresponding to the peak of the dose response curve, was selected for subse-
quent experiments comparing the effects of the test compounds on nicotinic receptor-mediated
responses in SH-SY5Y cells.
Effect of the test compounds on SH-SY5Y cells
Each compound was tested on SH-SY5Y cells at a range of concentrations similar to those
tested on CN21 cells. When tested at 100 μM, the C1-C4 compounds had no significant effect
on the responses (Fig 5) and therefore only C4-C10 were characterised at a larger range of con-
centrations. All of these compounds produced a concentration-dependent inhibition of the
nicotinic response in SH-SY5Y cells (Fig 6). The antinicotinic inhibitory potency of the series
of compounds increased with longer linker length (Table 1). In contrast to the results in CN21
cells, all the Hill slope values (Table 1) were more negative than -1.
In separate experiments using potassium depolarisation (not shown), it was verified that the
inhibitors had no effect on Ca2+ responses from activation of L-type calcium channels.
Fig 2. Concentration-response relationship for ACh in CN21 cells. This graph shows the effect of ACh (in
the presence of 20 μM atropine) on the fluorescence response measured in CN21 cells. Data are displayed
as the mean ± SEM of four replicates on a single plate. The sigmoidal concentration-response curve was
fitted for concentrations between 3 x 10−7 and 3 x 10−4 M. Best fit values: EC50 = 5.0 × 10
-6 M; Log EC50 =
-5.3; Hill slope = 1.7
doi:10.1371/journal.pone.0135811.g002
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Inhibition of acetylcholinesterase
The inhibitory potency of the series of compounds to acetylcholinesterase also increased with
longer linker length (Table 2). The C1 to C4 compounds had a limited effect on the enzyme
activity at concentrations up to 1 mM, but the C5 to C10 compounds inhibited acetylcholines-
terase activity with increasing potency, with the C9 and C10 compounds having IC50 values
less than 1 μM. Table 2 also shows previously-published LD50 data for some of the compounds
[24, 25] and, for comparison, some common oximes [26].
Discussion
The results of this study demonstrate that bispyridinium compounds inhibit nicotinic recep-
tor-mediated calcium responses in CN21 and SH-SY5Y cells and show a similar structure-
activity relationship in both cell lines. There was a profound effect of altering the polymethy-
lene linker length between the pyridine rings.
Fig 3. Influence of linker length on the effect of the bispyridinium compounds in CN21 cells. The Ca2+
response to ACh (10 μM) was measured in CN21 cells using a FlexStation plate reader in the presence of
different concentrations of the test compounds. Data are displayed as the mean ± SEM of three experiments
performed in duplicate on each plate. Curves were fitted with a standard four-parameter logistic equation (see
text). The fit did not converge for the C1 compound (MB775).
doi:10.1371/journal.pone.0135811.g003
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Mechanism of Ca2+ responses in CN21 and SH-SY5Y cells
The Ca2+ that produces the increase in fluorescence in the CN21 cell assay appears to be enter-
ing the cell through the cation-selective nicotinic ion channel [27]. Firstly, atropine completely
blocked the muscarinic component of the ACh-induced Ca2+ response in these cells, the
remaining response being abolished by the nicotinic antagonist d-tubocurarine. The response
Table 1. Inhibition of nicotinic responses in CN21 and SH-SY5Y cells.
CN21 SH-SY5Y
Test compound n Log IC50 (M) Hill slope Log IC50 (M) Hill slope
MB775 1 DNC DNC - -
MB520 2 -2.06 ± 0.04 -0.75 ± 0.06 - -
MB408 3 -2.37 ± 0 26 -0.73 ± 0.06 - -
MB444 4 -2.51 ± 0.15 -0.72 ± 0.05 -3.27 ± 0.04 -1.81 ± 0.26
MB442 5 -2.56 ± 0.16 -0.60 ± 0.13 -4.01 ± 0.04 -2.10 ± 0.40
MB776 6 -3.50 ± 0.32 -0.50 ± 0.02 -4.54 ± 0.04 -1.88 ± 0.24
MB777 7 -4.81 ± 0.23 -0.72 ± 0.01 -4.43 ± 0.05 -1.80 ± 0.30
MB505 8 -5.30 ± 0.20 -0.99 ± 0.07 -4.76 ± 0.03 -1.74 ± 0.22
MB778 9 -5.94 ± 0.11 -1.56 ± 0.11 -5.38 ± 0.04 -1.66 ± 0.20
MB779 10 -6.05 ± 0.17 -1.34 ± 0.14 -5.78 ± 0.03 -1.28 ± 0.09
Log IC50 values for inhibition of nicotinic responses in CN21 and SH-SY5Y cells by the test compounds. Data show mean ± SEM. All values were
obtained by best-ﬁt of the Hill-equation as described in the methods section. DNC = ﬁt did not converge.
doi:10.1371/journal.pone.0135811.t001
Fig 4. Concentration-response relationship for nicotine-evoked calcium responses in SH-SY5Y cells.
The graph shows the inhibitory effect of the C10 bispyridinium compound MB779. Open circles, nicotine
alone; closed circles, nicotine + MB 779 (2 μM). Data are displayed as the mean ± SEM of two experiments
with eight replicates on each plate.
doi:10.1371/journal.pone.0135811.g004
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is therefore not due to muscarinic receptor-induced Ca2+ release from intracellular stores [13].
Secondly, depolarisation of the cells with KCl failed to elicit a calcium response, indicating that
they do not express voltage-gated Ca2+ channels (VGCCs). This conclusion is in agreement
with both functional [28] and genetic [29] assessments of TE671 cells (the cell line from which
CN21 was derived), in which no VGCCs were found. [28] also showed that omission of Ca2+
from the extracellular solution abolished the response to ACh and that neither treatment with
K+ nor the L-type Ca2+ channel activator (-)BayK8644 produced an increase in intracellular
Ca2+. Although it is conceivable that Ca2+-induced Ca2+ release would further increase the cal-
cium response, it can be surmised from this evidence that the response in CN21 cells depends
on Ca2+ influx through the nicotinic ion channel when activated by ACh.
In SH-SY5Y cells, the nicotinic receptor-activated Ca2+ influx is due to influx through Ca2+
permeable nAChRs as well as activation of a number of parallel pathways [30], in particular
due to the presence of voltage-activated Ca2+ channels [31] and Ca2+-mediated Ca2+ release.
Nevertheless, since the specific nicotinic receptor inhibitors mecamylamine and d-tubocura-
rine completely inhibit the responses, the different sources of cytosolic Ca2+ rise are secondary
to nicotinic receptor activation. The effect of the bispyridinium compounds on nicotine-acti-
vated Ca2+ responses was therefore taken as the inhibitory effect on nAChRs.
Inhibition of nicotinic receptor mediated responses
The inhibitions of nicotinic responses produced by the compounds in the two cell types are
compared in Table 1 and Fig 7. In both cell types, the inhibitory potency (indicated by IC50) of
the series increased with longer linker length. The clear relationship between increasing chain
Fig 5. Inhibition of nicotinic responses in SH-SY5Y cells.Ca2+-responses were induced by nicotine
(50 μM) and the test compounds were all applied at a concentration of 100 μM. Data are displayed as the
mean ± SEM of two experiments with eight replicates on each plate. ** significant difference from control
(p<0.01, ANOVA with Dunnet’s post hoc test).
doi:10.1371/journal.pone.0135811.g005
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length and increasing potency suggests that either the relative positions of the charged nitrogen
groups or the size of the molecule are the most important factors in determining the level of
nicotinic antagonism for this series of compounds. This relationship was more marked for
CN21 cells than for SH-SY5Y (slopes of -0.575 and -0.402, respectively), but the IC50 values in
both cell types were similar for each compound, particularly for those with linker lengths
greater than C6. In CN21, but not in SHSY5Y, there was a change in the slope of the relation-
ship between C5 and C6. Our series of compounds has similarities to the polymethylene bistri-
methylammonium series (Me3N
+(CH2)nN
+Me3 2X
-) studied by [15], who also commented on
an abrupt change in the slope of the relationship for neuromuscular block around their C6
compound and suggested that this may indicate different pharmacological actions. They also
found that, as with our compounds, the neuromuscular blocking potency increased up to C10.
For CN21 cells, the Hill coefficient was less negative than -1 for the C1 to C7 compounds,
but then became more negative for longer linker lengths (C8 to C10). In contrast, in SH-SY5Y
cells, it was closer to -2 for many of the compounds, becoming less negative as the linker length
increased. It is conceivable that the difference in Hill coefficient between the two cell lines
reflects the different subunit composition of the receptors in the two cell lines. CN21 cells
express both foetal (α1-γ-α1-ß1-δ) and adult (α1-ε-α1-ß1-δ) human muscle nAChRs [13, 18],
while the SH-SY5Y cell line expresses several nicotinic receptor subunits (α3, α5, α7, β2 and
β4), giving rise to multiple nicotinic receptor subtypes [19].
Fig 6. Influence of linker length on the effect of the test compounds in SH-SY5Y cells. The Ca2+
response to nicotine (50 μM) was measured in SH-SY5Y cells using a Fluostar Optima plate reader. Data are
displayed as the mean ± SEM of two experiments with eight replicates on each plate. Curves were fitted were
fitted with a standard four parameter logistic equation (see text).
doi:10.1371/journal.pone.0135811.g006
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Table 2. Inactivation of human acetylcholinesterase and intravenous toxicities in mice.
Compound n AChE IC50 (μM) Log AChE IC50 (M) LD50 iv mice (mg kg
-1)
Bispyridinium seriesa
MB775 1 >1000 >-3 -
MB520 2 >1000 >-3 225
MB408 3 >1000 >-3 180
MB444 4 >1000 >-3 55
MB442 5 700 -3.15 32
MB776 6 70 -4.15 26
MB777 7 20 -4.70 -
MB505 8 1.4 -5.85 -
MB778 9 0.2 -6.70 -
MB779 10 0.5 -6.30 15
Common oximesb
HI-6 - - - 178
P2S - - - 116
2-PAMCl - - - 93
Obidoxime - - - 70
IC50 values for inactivation of human acetylcholinesterase and intravenous toxicities in mice for the test compounds and some oximes commonly used to
treat nerve agent poisoning.
a LD50 data for dibromide salt variants of the MB compounds taken from [24] and [25].
b Averaged LD50 data from [26].
doi:10.1371/journal.pone.0135811.t002
Fig 7. Relationship between polymethylene linker chain length and log IC50. Data are shown for CN21
(open blue triangles) and SH-SY5Y (closed red circles) cells. Solid lines show linear regression fits of the
data for the two data sets: CN21, y = -0.575x - 0.450, r2 = 0.936; SHSY5Y, y = -0.402x - 1.799, r2 = 0.980.
Broken lines show the 95% confidence intervals of the fits.
doi:10.1371/journal.pone.0135811.g007
Antinicotinic Bispyridinium Compounds
PLOS ONE | DOI:10.1371/journal.pone.0135811 August 14, 2015 12 / 16
Some bispyridinium compounds have been shown to block the open channel of the nico-
tinic receptor, a form of noncompetitive inhibition [12, 13], although a number of different
mechanisms of action could be responsible for the effects of the test compounds in this study.
Compounds which inhibited the response could be competitive or non-competitive antagonists
at the nicotinic receptor, or agonists producing desensitisation or partial activation. Due to the
limitations of the Ca2+ mobilisation fluorescence assay [32], it was not possible to confirm
competitive or non-competitive mechanisms of action of these compounds [13]. Therefore,
elucidation of the exact mechanism of the block will require further experiments, for example
using a single-channel assay [13].
In a previous study, we showed that MB327, a 4-tert-butyl substituted analogue of MB408,
produced open-channel block characterised by rapid, flickering bursts of openings and a reduc-
tion in the mean open time [13]. The effect of this would be not only to reduce the amplitude
of the endplate current (and hence of the endplate potential), but also to shorten its duration.
This would be expected to counteract the prolongation of the endplate potential by an AChE
inhibitor and the subsequent depolarisation block during repetitive stimulation. Although
effects on receptor desensitisation have not been investigated and cannot be ruled out, the alle-
viation of depolarisation block is consistent with the ability of MB327 to reverse the tetanic
fade produced by soman and to restore the shape of the tetanus in guinea-pig phrenic-nerve
hemidiaphragm preparations [13]. Furthermore, the di(methanesulfonate) salt of this com-
pound has been shown to increase protection against tabun, sarin and soman when used as
part of a combination therapy in guinea-pigs [13, 14]
Inhibition of acetylcholinesterase
As well as inhibiting nicotinic receptor-induced Ca2+ responses, the test compounds also inhib-
ited human acetylcholinesterase activity in vitro. As with the inhibition of nAChRs, the potency
increased with increasing linker length, again suggesting that either the relative positions of the
charged nitrogen groups or the size of the molecule are important factors in determining the
level of activity for this action in these compounds. A similar relationship between anticholin-
esterase potency and chain length was reported by [15] for their polymethylene bistrimethy-
lammonium compounds.
Toxicity of the compounds
Toxicity data have been published for dibromide salts of some of these bispyridinium com-
pounds [24, 25]: these show that the LD50 in mice decreases as the linker chain length increases
(Table 2). The increasing potency of inhibition of both the nicotinic response and acetylcholin-
esterase activity produced by increasing the chain length of these compounds could be at least
partly responsible for increasing toxicity through the series. The LD50 values indicate that the
shorter chain analogues (C2 and C3) have toxicities similar to those of some of the oximes
used to treat organophosphorus poisoning.
Clinical and therapeutic considerations
Some of the compounds evaluated in this study were weak inhibitors of the nicotinic response
and failed to block the response completely over the concentration range examined here. In
CN21, but not in SH-SY5Y, the concentration-response relationships for these compounds
tended to have shallower Hill slopes than those exhibited by the potent blockers. A compound
with a shallow Hill slope could have more utility as a medical therapy against the nicotinic
effects of organophosphorus poisoning, because it may have a larger therapeutic window
before the compound itself becomes toxic through overwhelming block of nicotinic receptor
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function. Indeed, the 4-tert-butyl substituted analogue MB327 (with a C3 linker), which we
previously showed to produce recovery of neuromuscular function following soman poisoning
in vitro and to protect against nerve agent poisoning in vivo [13, 14], had a log IC50 [M] of
-2.86 ± 0.16 (mean ± SEM) in the CN21 calcium response assay, with a Hill slope of
-0.89 ± 0.10 [13]. More recently, we have demonstrated similar protection against soman poi-
soning using MB442, the C5 linker compound described in this study (unpublished data).
Compounds that exhibit a steep concentration-response curve may require more careful titra-
tion of the therapeutic dose.
The similarity of the IC50 values in CN21 and SH-SY5Y assays suggests that the inhibition is
not specific for particular subtypes of the nicotinic receptor, in particular since SH-SY5Y con-
tains a number of channels with different stoichiometry of α and β subunits. This raises the
possibility that some of these compounds could be used to treat the nicotinic effects of organo-
phosphorus poisoning in the central nervous system if they could be delivered into the brain.
Like oximes, these quaternary compounds would not be expected to cross the blood-brain bar-
rier in significant quantities; however, there have been some recent studies on improving the
penetration of oximes into the brain [33–35] and it is likely that these approaches could also be
applied to these antinicotinic compounds.
Conclusions
This study has demonstrated the ability of bispyridinium compounds to inhibit both muscle
and neuronal nAChRs and has shown a clear structure-activity relationship based on the linker
length between the two pyridinium moieties. The toxicities of the shorter chain analogues com-
pare favourably to those for oximes used to treat organophosphorus poisoning [24, 25]. Fur-
thermore, previous work has shown that a 4-tert-butyl substituted analogue of the C3
compound protected against nerve agent poisoning in guinea-pigs [13, 14]. Together, these
results indicate that non-oxime bispyridinium compounds may be considered as promising
candidates for the treatment of the nicotinic effects of organophosphorus poisoning, and that
structure-activity relationships can be used to optimise molecular structures for therapeutic
use.
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